SCIENCE@home

Best practice guide for the treatment of REM sleep behavior disorder (RBD).

R. Aurora,Rochelle S. Zak,R. Maganti,Sanford H. Auerbach,Kenneth R. Casey,S. Chowdhuri,Anoop Karippot,K. Ramar,D. Kristo,T. Morgenthaler

Published 2010 in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

ABSTRACT

SUMMARY OF RECOMMENDATIONS Modifying the sleep environment is recommended for the treatment of patients with RBD who have sleep-related injury. Level A Clonazepam is suggested for the treatment of RBD but should be used with caution in patients with dementia, gait disorders, or concomitant OSA. Its use should be monitored carefully over time as RBD appears to be a precursor to neurodegenerative disorders with dementia in some patients. Level B Clonazepam is suggested to decrease the occurrence of sleep-related injury caused by RBD in patients for whom pharmacologic therapy is deemed necessary. It should be used in caution in patients with dementia, gait disorders, or concomitant OSA, and its use should be monitored carefully over time. Level B Melatonin is suggested for the treatment of RBD with the advantage that there are few side effects. Level B Pramipexole may be considered to treat RBD, but efficacy studies have shown contradictory results. There is little evidence to support the use of paroxetine or L-DOPA to treat RBD, and some studies have suggested that these drugs may actually induce or exacerbate RBD. There are limited data regarding the efficacy of acetylcholinesterase inhibitors, but they may be considered to treat RBD in patients with a concomitant synucleinopathy. Level C.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-96 of 96 references · Page 1 of 1

CITED BY

Showing 1-100 of 439 citing papers · Page 1 of 5

12345
Next